A study demonstrated that in an orthotopic HCC mouse model, FASN inhibition enhanced the stability of major histocompatibility complex class I (MHC-I) molecules and synergized with anti-PD-L1 blockade to significantly inhibit tumor growth (333). The gene discussed is CD274; the disease is hepatocellular carcinoma.